GLP-1 Medications and Menopause: Weight, Muscle, Bone, Hormone Therapy and What the Trials Show

If you’re in perimenopause or past menopause and taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), there’s less menopause-specific data than you might expect: no FDA label mentions menopause, and no large trial was designed for this stage of life. This guide pulls together what is known about your body, the trials, hormone therapy, muscle and bone. If your question is about your period, see period changes on Ozempic, Wegovy, Mounjaro or Zepbound.

What changes in your body at menopause

Menopause is confirmed once you’ve gone a full year without a period or spotting. According to the National Institute on Aging, most women start the transition between 45 and 55, and the average age of menopause in the US is 52. During the transition, the way the body uses energy and stores fat changes, weight comes on more easily, and bone density, body shape and physical function can change too^[5].

The SWAN study has followed US women through midlife and measured body composition with DEXA, a low-dose X-ray scan. In a 2019 analysis, fat gain doubled in speed at the start of the transition and lean mass began to decline. Those changes continued until about 2 years after the final period, then leveled off. Weight itself kept rising at the same pace as before^[6]. In other words, the scale may not show much while your body composition shifts.

A second analysis of 380 women found that visceral fat, the fat around the abdominal organs, started increasing with the transition, by about 6% a year; waist and hip measurements picked this up poorly^[7]. That’s one reason BMI says little at this stage, as I explain alongside the BMI calculator.

What the FDA labels say

I searched the US labels for “menopause”, “estrogen” and “fracture”. Here’s what’s relevant to this stage of life.

Labels checked on October 5, 2026.

The fracture line. In Wegovy’s cardiovascular outcomes trial, hip and pelvis fractures were reported in 1% of women on Wegovy (24 of 2,448) vs. 0.2% on placebo (5 of 2,424), and in 2.4% of people 75 and older (17 of 703) vs. 0.6% (4 of 663)^[1]. The label gives the numbers without explaining the cause. Neither tirzepatide label includes a similar finding^[2,3].

What the trials show by menopausal stage

Tirzepatide: the SURMOUNT analysis

A later analysis, funded by Lilly, sorted the women in SURMOUNT-1, SURMOUNT-3 and SURMOUNT-4 by reproductive stage. The trials hadn’t recorded stage, so it was estimated from medical history, occasional hormone tests and, mostly, age. For example, every woman aged 55 or older counted as postmenopausal^[8].

SURMOUNT-1 included 1,707 women: 697 before menopause (average age 34), 429 in perimenopause (45) and 581 after menopause (58). On 15 mg of tirzepatide for 72 weeks^[8]:

SURMOUNT-3 and SURMOUNT-4 showed similar results^[8].

Its limits: stage is an estimate, menopause symptoms weren’t measured, and each number compares tirzepatide with placebo within a group. It also doesn’t separate fat from muscle. A DEXA substudy of SURMOUNT-1 did, in 160 people, 73% of them women: about 75% of the weight lost was fat and 25% lean mass, with similar proportions in most subgroups by sex and age, including people 65 and older^[9]. For the bigger picture, see how much weight you can lose on GLP-1 medications.

Semaglutide: no analysis by stage

I haven’t found any analysis of the STEP trials by menopausal stage on PubMed. A 2026 position statement from the Spanish Menopause Society, published in Maturitas, sums it up: semaglutide has the most menopause-specific evidence, but it’s limited and mostly observational, and tirzepatide needs menopause-specific studies^[10]. A 2026 review adds that losing lean mass doesn’t always mean losing strength or function^[11].

Trials underway

• SYNCHRONIZE-HERA, sponsored by Boehringer Ingelheim: 600 women aged 45 to 65 in perimenopause or after menopause, without diabetes, on survodutide or placebo for 52 weeks. It measures weight and menopause symptoms. It isn’t recruiting yet; the estimated start is October 31, 2026^[12].
• A Mayo Clinic pilot: 40 postmenopausal women with obesity on tirzepatide or placebo for 24 weeks, with the frequency and severity of hot flashes as the main outcome. It has been recruiting since April 2026^[13].

Hormone therapy and GLP-1 medications

Menopausal hormone therapy (MHT, often called HRT) uses estrogen plus, if you still have a uterus, a progestogen to protect it. According to The Menopause Society’s 2022 position statement, it’s the most effective treatment for hot flashes and genitourinary symptoms such as vaginal dryness, and it prevents bone loss and fractures. Its risks depend on the type, dose, duration, route and when it’s started^[18]. It isn’t a weight-loss treatment: the Spanish Menopause Society says it shouldn’t be started just to boost weight loss^[10].

Do you lose more weight on both?

The only published data I found is a retrospective Mayo Clinic study of 106 postmenopausal women on semaglutide. The 16 on hormone therapy lost 16% of their weight at 12 months, vs. 12% for the 90 who weren’t. The difference held after adjusting for other factors, but the authors call for larger studies^[14]. Without randomization, women who use hormone therapy may differ in other ways; the Spanish Menopause Society treats it as a hypothesis^[10].

A randomized trial is underway in Switzerland: 96 early postmenopausal women with prediabetes or type 2 diabetes get an estradiol patch (plus progesterone if they have a uterus), semaglutide or both. The main outcome is HbA1c, a measure of average blood sugar, at 12 weeks; weight and menopause symptoms are secondary outcomes. It’s no longer recruiting, with primary completion expected in December 2026^[15].

Interactions: medications taken by mouth

These drugs slow stomach emptying, which can change how oral medications are absorbed.

• Zepbound and Mounjaro. The labels ask for caution with oral medications and monitoring of narrow-therapeutic-index drugs. Their advice to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase applies to oral hormonal contraceptives; non-oral ones should not be affected^[2,3]. In the Zepbound label’s studies, the effect on stomach emptying was greatest after a single 5 mg dose and smaller after later doses^[2].
• Wegovy. The label says to monitor the effects of oral medications and consider closer monitoring for narrow-therapeutic-index drugs; semaglutide caused no clinically significant change in ethinyl estradiol or levonorgestrel levels^[1].

None of the labels mention hormone therapy. A 2026 review points out that the only absorption study with tirzepatide used a birth control pill, and there’s no data on the progestogens used in MHT; any effect, still unproven, would be concentrated at the start and during dose increases^[16]. There’s also one published case: a 51-year-old woman on oral estrogen had worse hot flashes while her semaglutide dose was going up, and improved when it was increased more slowly. One case only raises a hypothesis^[17].

If you use hormone therapy, make sure both your GLP-1 prescriber and your gynecologist know, and whether it’s a pill, patch or gel. The NIA says to see your doctor if you bleed or spot again after more than a year without a period^[5].

Muscle and bone

Menopause already brings lean-mass and bone changes^[5,6], and losing weight on a GLP-1 medication also takes some lean mass^[1,2,9]. On bone, a 2025 advisory from four US obesity, nutrition and lifestyle-medicine societies notes that large, fast weight loss (14% or more over 3 to 4 months) is linked to bone loss, with greater losses in women and older people^[19].

The most direct evidence is a Danish phase 2 trial of 64 adults at increased fracture risk, 55 of them postmenopausal women, with an average age of 63. After 52 weeks on 1 mg of semaglutide a week, bone density at the lumbar spine and hip was slightly lower than on placebo. A marker of bone breakdown also rose, possibly because of the weight loss, according to the authors. It’s a small trial and it didn’t measure fractures^[22].

Another Danish trial, of 195 adults aged 18 to 65 (64% of them women), tested liraglutide, an older GLP-1 medication. Over a year, liraglutide alone lowered hip and spine bone density more than exercise alone; with liraglutide plus exercise, bone density didn’t change compared with placebo^[20]. It wasn’t focused on menopause.

The Spanish Menopause Society asks clinicians to factor in fracture risk, resistance exercise, enough protein and structured monitoring of physical and metabolic function^[10]. What general guidance says:

• Strength. The Physical Activity Guidelines for Americans call for muscle-strengthening activity at least 2 days a week^[21]. For people on a GLP-1 medication, the 2025 advisory suggests strength training at least 3 times a week^[19]. To get started, see strength training on GLP-1 medications.
• Protein. The same advisory cites 0.8 g per kg a day (0.36 g/lb) for adults and 1.2 to 1.6 g/kg (0.54 to 0.73 g/lb) proposed during active weight loss, never below 0.4 to 0.5 g/kg (0.18 to 0.23 g/lb). It also lists perimenopause and menopause among the factors that raise the risk of muscle loss when protein intake is low^[19]. More in protein and muscle on GLP-1 medications; the protein calculator gives a ballpark figure.
• Measuring. What each test measures is in bioimpedance scale vs. DEXA. Whether you need a bone density scan is your doctor’s call.

Hot flashes, sleep and mood

According to the NIA, a hot flash can last from 30 seconds to 10 minutes, night sweats can break up sleep, and some women feel moodier or more irritable around menopause^[5].

What hasn’t been studied. I haven’t found any published trial of semaglutide or tirzepatide on PubMed that measured hot flashes or other menopause symptoms; the SURMOUNT analysis calls for that research^[8]. The first data will come from the trials underway: the Mayo Clinic pilot, SYNCHRONIZE-HERA and the Swiss trial, which tracks menopause symptoms as a secondary outcome^[12,13,15].

Sleep. Zepbound is FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity^[2]; I cover it in Zepbound for sleep apnea. In postmenopausal women specifically, semaglutide’s effect on breathing during sleep is poorly studied^[11]. How sleep, stress and appetite interact is in sleep, stress and appetite.

Mood. Beyond the case above^[17], I haven’t found studies on mood during menopause with these drugs. If you notice changes, log them in the symptom diary and bring it to your appointment.

Questions to ask your doctor

Some questions for your doctor or gynecologist:

• If I’m on hormone therapy, is there anything to watch when I start the GLP-1 medication or when the dose goes up? Does it matter whether it’s a pill or a patch?
• Does it make sense to assess my fracture risk or get a bone density scan?
• How much protein and what kind of exercise are reasonable for me?
• Which symptoms should I track, such as hot flashes, bleeding or sleep, and when should I call?

You can take them with you on the doctor visit checklist.

FAQ

Can I take Zepbound or Wegovy while on HRT?

None of the US labels mention menopausal hormone therapy^[1,2,3,4]. The tirzepatide labels ask for caution with oral medications^[2,3], and there’s no data on the progestogens used in MHT^[16]. That decision belongs to your doctor and your gynecologist; tell both everything you take.

Does hormone therapy help you lose more weight on semaglutide?

One retrospective study suggests it (16% vs. 12% at 12 months), but only 16 women were on hormone therapy^[14]. The Spanish Menopause Society says MHT shouldn’t be started just to lose more weight^[10].

Do you lose less weight on Zepbound after menopause?

In SURMOUNT-1, on 15 mg of tirzepatide, women after menopause lost 23% of their weight and women who hadn’t reached it lost 26%, vs. 2% to 3% on placebo^[8]. Stage was estimated mostly from age, so the gap may reflect age or other factors.

Do Ozempic or Zepbound help with hot flashes?

Nobody knows yet: the SURMOUNT trials didn’t measure them^[8], and I haven’t found any published trial that did. A tirzepatide pilot has them as its main outcome^[13]. According to The Menopause Society, hormone therapy is the most effective treatment for hot flashes^[18]; whether it suits you is for your doctor or gynecologist to assess.

Do GLP-1 medications weaken bones after menopause?

In a small semaglutide trial, 55 of the 64 participants were postmenopausal women at increased fracture risk: after a year, their hip and spine bone density was slightly lower than on placebo, and fractures weren’t measured^[22]. I haven’t found a similar trial of tirzepatide. The US Wegovy label reports more hip and pelvis fractures in women on Wegovy than on placebo (1% vs. 0.2%)^[1]. With liraglutide, adding exercise preserved bone density^[20]. Ask your doctor whether your fracture risk should be assessed.